FDA delays decision on Heron’s twice-rejected nausea drug

Damian Garde

Heron Therapeutics, pushing to finally win approval for a long-delayed treatment for chemotherapy-induced , will have to wait another month or so as the FDA has put off its plans to weigh in this week.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS